Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 11, 2015Current Opinion in HIV and AIDSOpen Access

Antibody engineering for increased potency, breadth and half-life

View Full Paper
Ask AI
Bookmark
Share

Authors

SSStuart A. SieversLSLouise ScharfAWAnthony P. West

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Sievers et al. (2015) studied this question.

synapsesocial.com/papers/6a70ced96ceb2bbd16dfff7ahttps://doi.org/10.1097/coh.0000000000000148
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target2009 · 1,762 citations
  2. 2Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers2008 · 98 citations
  3. 3Anti-HIV Double Variable Domain Immunoglobulins Binding Both gp41 and gp120 for Targeted Delivery of Immunoconjugates2012 · 26 citations
  4. 4A Double-Mimetic Peptide Efficiently Neutralizes HIV-1 by Bridging the CD4- and Coreceptor-Binding Sites of gp1202014 · 18 citations